Clinical Trials Logo

Clinical Trial Summary

The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy (FECD)) is beginning to be dismembered. One of the most common genetic anomalies is a triplet repetition in one of the introns of the Transcription Factor 4 (TCF4) gene located on chromosome 18. However, the number of repetitions varies greatly from one patient to another.


Clinical Trial Description

The intent of that study was to analyse if there is a relationship between the number of triplet repetitions and the rate of disease progression. This knowledge would make it possible to personalize the care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03974230
Study type Observational
Source Centre Hospitalier Universitaire de Saint Etienne
Contact
Status Completed
Phase
Start date August 1, 2019
Completion date December 14, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04440280 - Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy Phase 2
Active, not recruiting NCT05376176 - A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) Phase 2
Recruiting NCT05826353 - A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Phase 3
Recruiting NCT04387331 - The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK
Recruiting NCT05795699 - A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Phase 3
Active, not recruiting NCT04894110 - Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema Phase 1
Completed NCT04520321 - A Phase 1/ Phase 2 Study of TTHX1114(NM141) Phase 1/Phase 2
Withdrawn NCT05052554 - Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 Phase 1